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HPC2/ELAC2 has been identified as a prostate cancer (CaP) susceptibility gene. Two common missense variants
in HPC2/ELAC2 have been identified: a SerrLeu change at amino acid 217, and an AlarThr change at amino
acid 541. Tavtigian et al. reported that these variants were associated with CaP in a sample of men drawn from
families with hereditary CaP. To confirm this report in a sample unselected for family history, we studied 359
incident CaP case subjects and 266 male control subjects that were frequency matched for age and race and were
identified from a large health-system population. Among control subjects, the Thr541 frequency was 2.9%, and
the Leu217 frequency was 31.6%, with no significant differences in frequency across racial groups. Thr541 was
only observed in men who also carried Leu217. The probability of having CaP was increased in men who carried
the Leu217/Thr541 variants (odds ratiop 2.37; 95% CI 1.06–5.29). This risk did not differ significantly by family
history or race. Genotypes at HPC2/ELAC2 were estimated to cause 5% of CaP in the general population of
inference. These results suggest that common variants at HPC2/ELAC2 are associated with CaP risk in a sample
unselected for family history or other factors associated with CaP risk.
There is substantial evidence that prostate cancer (CaP;
MIM 176807) has a hereditary component. Linkage of
CaP to HPC1 (MIM 601518; Smith et al. 1996, Xu et
al. 2000), PCAP (MIM 602759; Berthon et al. 1996),
HPCX (MIM 300147; Xu et al. 1998) and CAPB (MIM
603688; Gibbs et al. 1999) has been reported, but these
genes have yet to be isolated and may explain a relatively
small proportion of disease in the general population.
CaP has also been associated with common variants in
genes involved in steroid hormone metabolism—
including AR (Giovannuci et al. 1997), SRD5A2 (Mak-
ridakis et al. 1999; Jaffe et al. 2000), andCYP3A4 (MIM
124010; Rebbeck et al. 1998), vitamin D metabolism
(Ingles et al. 1997), and carcinogen metabolism (Reb-
beck et al. 1999). The HPC2/ELAC2 gene on chro-
mosome 17p has been identified, by family studies, as
being associated with CaP risk (Tavtigian et al. 2000),
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and at least two common missense variants in HPC2/
ELAC2 have been identified. The function of this gene
has yet to be elucidated, and the functional significance
of the common missense mutations is not known. How-
ever, significant cross-species identity of HPC2/ELAC2
exists across a wide range of organisms (Tavtigian et al.
2000). The Ala541Thr missense variant in HPC2/
ELAC2 lies adjacent to a highly conserved histidine mo-
tif, suggesting that the presence of a Thr541 allele may
have deleterious effects on the function of the protein
encoded by this gene.
To evaluate whether HPC2/ELAC2 genotypes are as-
sociated with nonhereditary CaP risk, a sample of 432
incident CaP case subjects was identified through rep-
resentative clinics of the University of Pennsylvania
Health System (UPHS) between September 1994 and
December 1999. The UPHS counts 11 million patient
visits per year at the Hospital of the University of Penn-
sylvania, its ten affiliate hospitals, and ∼130 Clinical
Care Associates practices located throughout the met-
ropolitan Philadelphia region. Case status was confirmed
by medical records review by use of a standardized ab-
straction form. Men were excluded from this study if
they reported having exposure to finasteride (Proscar)
at the time of their CaP diagnosis. Patients who were
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Figure 1 Agarose gel visualization of (A) the Ser217Leu polymorphism and (B) the Ala541Thr polymorphism. PCR product sizes after
restriction enzyme digestion with TaqI (for Ser217Leu) or Fnu4HI (for Ala541Thr) are shown.
nonincident case subjects (i.e., those diagnosed 112 mo
prior to the date of study ascertainment) or who had a
prior diagnosis of cancer at any site also were excluded.
After these exclusions, a sample of 359 patients with
CaP was available for analysis, although the effective
sample size for some analyses was smaller because of
missing data.
Six hundred twenty-eight men attending UPHS gen-
eral medicine clinics were ascertained as potential con-
trol subjects. These clinics see a patient population that
is demographically similar to those seen in the urologic
oncology clinics at UPHS. These men were ascertained
concurrently with the individuals who had CaP (i.e.,
between September 1994 and December 1999). Control
subjects were excluded from analysis if they ever had an
elevated prostate-specific antigen test (i.e., 4 ng/ml), if
they had ever had an abnormal digital rectal examina-
tion (DRE), if they had a previous cancer diagnosis, or
if they reported having had exposure to finasteride (Pros-
car) at the time of study ascertainment. After these ex-
clusions were applied, 383 control subjects were avail-
able for matching to case subjects. Control subjects were
frequency matched to patients with CaP on age (5
years) and race. After exclusion and matching criteria
were applied, a set of 266 control subjects was available
for analysis, although the effective sample size for some
analyses was smaller because of missing data. Allele-
frequency estimates were made in the 383 eligible con-
trol subjects (rather than the subset of matched control
subjects) to limit the potential effect on allele-frequency
estimates that may be induced by matching on case-
subject characteristics.
Risk factor, medical history, and CaP diagnostic in-
formation was obtained by use of a standardized ques-
tionnaire and review of medical records. Information
collected included CaP occurrences in first- and second-
degree relatives; personal history of benign prostatic hy-
perplasia and vasectomy; previous cancer diagnoses;
demographic information, such as race, educational
level, and occupation; and CaP screening history. All
study subjects provided informed consent for partici-
pation in this research under a protocol approved by the
Committee for Studies Involving Human Subjects at the
University of Pennsylvania.
Genomic DNA for the present study was self-collected
by each study subject using sterile cheek swabs (Cyto-Pak
Cytosoft Brush, Medical Packaging Corporation) and was
processed using the protocol of Walker et al. (1999). All
PCR reactions were carried out using a master mix that
consisted of 4.00 ml of 5# CPCR buffer (0.1M TrisCl,
pH 8.8–9.0, 42.52 mM NaCl, 50 mM KCl, 50 mM
(NH4)2SO4, 10 mM MgSO4, and 0.5% Triton X-100),
0.4 ml of 10 mM dNTPs, 0.4 ml of each 10 mM primer,
and 0.1 ml of Platinum Taq (Life Technologies, Inc.) and
ddH2O, for a total reaction volume of 20 ml. Nested PCR
reactions were used to amplify the regions containing the
polymorphisms of interest. First, primers m5A (5′-CA-
TTCCCATGTATGAACGTCT-3′) and m5P (5′-ATAG-
TAAGCCCAGGAAGAAGGA-3′) were used to amplify
the region containing the Ser217Leu variant. These prim-
ers were amplified with a 25-cycle protocol of 95C for
3 min for 1 cycle; 96C for 30 s, 55C for 35 s, and 72C
for 45 s for 25 cycles; followed by an elongation cycle of
72C for 10 min. These PCR products then were diluted
1:5 and were used in a second PCR reaction at a final
dilution of 1:60. The second (nested) set of primers used
was m5B (5′-GTTTTCCCAGTCACGACGCATTCCCA-
TGTATGAACGTCT-3′) and m5Q (5′-AGGAAACAGC-
TATGACCATCTACAAGCATTACAAGGCAGAG-3′).
These primers amplified a 276-bp region using the same
protocol as described above, but with only 23 cycles
rather than 25. Finally, 5 ml of the final 276-bp PCR
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Table 1
Descriptive Characteristics of Case-Control Sample
Trait Control Subjects Case Subjects Comparison
Mean age in years (SD) 60.7 (10.0)a 61.3 (6.8)b ; df 1; c2x p 3.46 Pp .063
Race:
White 215 (85.3%) 306 (86.4%) FET Pp .611
Black 33 (11.4%) 37 (10.5%)
Other 7 (3.3%) 11 (3.1%)
Mean serum PSA in ng/ml (SD)d .80 (1.00) 8.33 (7.18) ; df 1; c2x p 400.06 P ! .0001
Family history of CaP:
No 236 (91.5%) 275 (79.7%) FET P ! .0001
Yes 22 (8.5%) 70 (20.3%)
a Range 41–84 years.
b Range 41–80 years.
c Kruskal-Wallis x2 approximation.
d Serum PSA was measured at time of diagnosis, in case subjects, and at most recent clinic visit, in
control subjects.
product was digested overnight with TaqIa (NEB) at
65C. Genotypes were visualized on a 3% agarose gel
(fig. 1A).
A second set of nested PCR reactions was used to am-
plify the Ala541Thr variant. Primers m15A (5′-CCA-
GCCTTTGTGTAAGTCTAC-3′) and m15P (5′-TCTGG-
GCAAGTTTGGAAGC-3′) were amplified with a 25-
cycle protocol consisting of 95C for 3 min for 1 cycle;
96C for 30 s, 55C for 35 s, and 72C for 45 s for 25
cycles; followed by an elongation cycle of 72C for 10
min. The products were then diluted 1:5 and were used
in a second PCR reaction at a final dilution of 1:60. The
second (nested) set of primers used was m15A (see above)
and m15RFLP.R′ (5′-AATTCTTGATAGGAAACAGCT-
ATGACCATCAGCTTTGTGGTCCAGCCCAAC-3′).
These primers were used to amplify a 419-bp region am-
plified using the same protocol as described above, but
with only 23 cycles rather than 25. Finally, 20 ml of the
final PCR product was then digested for 3 h with Fnu4HI
(NEB) at 37C. Genotypes were visualized on a 3% aga-
rose gel (fig. 1B).
Confirmation of genotype data was undertaken by
direct sequencing of 21 individuals identified by RFLP
analysis as carrying variant alleles and 8 individuals
identified by RFLP analysis as carrying wild-type gen-
otypes. All sequence results were consistent with the
RFLP analyses. These analyses were undertaken using
an automated ABI377 (ABI Prism), according to man-
ufacturer’s instructions.
In order to evaluate the relationship of Ser217Leu and
Ala541Thr variants with the probability of having CaP,
we constructed genotype classes that simultaneously
considered both missense variants. First, we grouped in-
dividuals into four genotype classes, to reflect the joint
effects of both missense changes. The following classes
were considered: (a) Ser/Ser and Ala/Ala individuals, (b)
individuals who carried any Thr541 variant on an Ser/
Ser background (no genotypes of this class were ob-
served), (c) individuals who carried any Leu217 variant
on an Ala/Ala background, and (d) individuals who car-
ried any Thr541 variant, which were always observed
on a background of a Leu217 allele. In addition, we
compared individuals who were Ala541 homozygotes
with individuals who carried any Thr541 allele. These
genotype classes allowed us to compare the joint effects
of both missense changes, and to evaluate the potential
increase in the deleterious effect of the presence of both
variants, relative to that of only one variant.
Genotype-disease associations were undertaken using
unconditional logistic regression. Analyses considered
the effect of genotype adjusted for potential confound-
ers, including age (at time of diagnosis, in case subjects,
and at time of study ascertainment, in control subjects),
family history (defined as one or more first-degree rel-
atives and/or two or more second-degree relatives), and
race (coded as a discrete variable with three levels: white,
black, or other). Subset analyses in whites only and in
men with no family history of CaP were also undertaken.
All P values were based on two-sided hypothesis tests.
Table 1 presents a description of the sample popula-
tion. The sample consisted of men aged 41–84 years,
∼85% of whom were white. The racial distribution of
our case-subject sample roughly reflects the UPHS pros-
tate cancer–patient population overall. Because of the
matching algorithm used here, there was no difference
in the distribution of age or race between case subjects
and control subjects. Consistently with most previous
reports, mean serum PSA levels were significantly higher
in case subjects than in control subjects, and case sub-
jects were significantly more likely to have a family his-
tory of CaP than were control subjects.
We estimated the Thr541 allele frequency in 383 con-
trol subjects to be 2.9% and the Leu217 allele frequency
to be 31.6%. We observed Thr541 alleles only in the
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Table 2
Case-Control Comparisons of HPC2/ELAC2 Genotypes
Ser217Leu
Genotype
Ala541Thr
Genotype Control Subjects Case Subjects
Total Sample
OR (95% CI)a
Whites
OR (95% CI)a
No Family
History of CaP
OR (95% CI)a
Ser/Ser Ala/Ala 121 (46.9%) 172 (47.9%) 1.0b 1.0b 1.0b
Ser/Ser Any Thr 0 0 … … …
Any Leu Ala/Ala 128 (49.6%) 160 (44.6%) 0.89 (0.63–1.25) 0.99 (0.69–1.43)c 0.90 (0.63–1.30)c
Any Leu Any Thr 9 (3.5%) 27 (7.5%) 2.37 (1.06–5.29) 2.23 (1.00–4.98)c 2.36 (1.01–5.56)c
Any Ala/Ala 249 (96.5%) 332 (92.5%) 1.0b 1.0b 1.0b
Any Any Thr 9 (3.5%) 27 (7.5%) 2.24 (1.02–4.90) 2.21 (1.01–4.85)c 2.25 (0.97–5.19)c
a OR adjusted by multiple logistic regression for age, race, and family history of CaP.
b Reference group.
c Breslow-Day test for homogeneity of OR indicates no differences among strata with .P 1 .5
presence of Leu217 alleles, consistent with the disequi-
librium between these alleles observed by Tavtigian et
al. (2000). Among whites, these frequencies were 3.2%
and 32.2%, respectively. Among blacks, these frequen-
cies were 0.8% and 28.4%, respectively. There were no
statistically significant differences in the Ser217Leu
(Fisher’s Exact Test [FET] ) or the Ala541ThrPp .531
(FET P value p .237) allele frequencies by race. Ge-
notype frequencies did not deviate from Hardy-Wein-
berg proportions in the sample as a whole, in whites, or
in blacks.
Genotype frequencies did not differ by decade of birth
in our sample for the combined Ser217Leu/Ala541Thr
genotype for either case subjects ( , df 4,2x p 2.478
) or control subjects ( , df 5,2Pp .649 x p 2.346 Pp
). In contrast to our results, Tavtigian et al. (2000).800
reported a moderate effect of birth cohort on the fre-
quency of the Ser217Leu and Ala541Thr variant fre-
quencies in their population. Specifically, the variant al-
lele frequencies appeared to differ in men born before
and after 1920. Although ∼20% of the sample of studied
by Tavtigian et al. (2000) was born before 1920, !3%
of our study subjects were born before 1920. Therefore,
our sample may be inadequate to detect the relatively
small birth cohort effect reported by Tavtigian and col-
leagues, if it exists in our population. Additional studies
that include a larger proportion of men from earlier birth
cohorts are required to evaluate a potential birth cohort
effect on genotype frequencies.
Leu217/Thr541 genotypes were significantly more
common among case subjects than control subjects (ta-
ble 2). Even after adjusting for age, race, and family
history of CaP, Leu217/Thr541 genotypes predicted CaP
risk (odds ratio [OR]p 2.37; 95% CI 1.06–5.29). This
result is similar to that reported by Tavtigian et al. (2000)
in their comparison of CaP case subjects and “divergent”
(i.e., nonfamilial) control subjects. Although the pro-
portions of family history–positive subjects and non-
whites were too small to allow formal tests of interac-
tion, the effect of this genotype did not appear to differ
substantially by family-history status or by race. In a
subset analysis (table 2), point estimates of CaP risk
associated with Leu217/Thr541 genotypes were not sub-
stantially different in whites only or family his-
tory–negative individuals only, compared with the total
sample.
Despite the report of Tavtigian et al. (2000) that sug-
gests that mutations in HPC2/ELAC2 explain some he-
reditary prostate cancer, there are a number of reasons
why the present study did not identify differences in the
relationship between genotype and disease by family his-
tory. First, the sample size may be too small to provide
sufficient statistical power to undertake analyses strati-
fied on family history, since only 8% of control subjects
and 20% of case subjects reported a family history of
prostate cancer. The present sample also consisted of
very few individuals from families in which prostate can-
cer might be considered “hereditary” in nature. Only
nine (1.4%) subjects in the present sample reported three
or more first- or second-degree relatives with prostate
cancer. Second, our family-history information was ob-
tained only by self-report of the case or control subjects,
and no validation of family history was undertaken. Un-
like most genetic-linkage studies, our study may have
relatively more misclassification on prostate cancer fam-
ily history, and this misclassification may affect our abil-
ity to detect effects of genotype by family history. Third,
it is possible that, although common HPC2/ELAC2
polymorphisms confer a greater-than-twofold increase
an individual’s prostate cancer risk, this effect may not
be strong enough to confer a significant family history
of CaP in the present study sample. Therefore, we con-
clude that only limited information about the role of
common missense variants at HPC2/ELAC2 and family
history of CaP can be learned from the present study.
Additional analyses were undertaken to evaluate the
relationship of Leu217/Thr541 genotypes with charac-
teristics of prostate tumors. Leu217/Thr541 genotypes
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Table 3
Case-Case Associations with HPC2/ELAC2 Genotype
Variable
Ser/Ser
Ala/Ala
Any Leu
Ala/Ala
Any Leu
Any Thr
Test Statistic
and P Value Ala/Ala Any Thr
Test Statistic
and P Value
Age at diagnosis (years) 61.8 60.6 61.1 x22p1.86; Pp.395 61.2 61.1 x
2
1p0.06; Pp.808
Median (mean) serum PSA
at diagnosis (ng/dl) 6.0 (7.6) 6.4 (8.4) 7.3 (11.3) x22p2.89; Pp.236
a 6.1 (7.9) 7.3 (11.3) x21p2.34; Pp.126
a
Gleason grade:
!6 6 (4.2%) 6 (4.6%) 0 (0%) 12 (4.4%) 0 (0%)
6–8 133 (93.0%) 121 (92.4%) 23 (95.8%) FET P p .905 254 (92.7%) 23 (95.8%) FET P p .509
18 4 (2.8%) 4 (3.1%) 1 (4.2%) 8 (2.9%) 1 (4.2%)
BPH:
Yes 29 (18.4%) 33 (22.3%) 6 (23.1%) FET P p .652 62 (17.2%) 6 (23.1%) FET P p .800
No 129 (81.7%) 115 (77.7%) 20 (76.9%) 244 (79.7%) 20 (76.9%)
Extracapsular extension:
Yes 28 (22.6%) 24 (21.4%) 5 (26.3%) FET P p .895 52 (22.0%) 5 (26.3%) FET P p .774
No 96 (77.4%) 88 (78.6%) 14 (73.7%) 184 (78.0%) 14 (73.7%)
a Kruskal-Wallis x2 approximation.
were not associated with an earlier age at diagnosis, the
existence of benign prostatic hypertrophy (BPH), Glea-
son grade, PSA at diagnosis, or extracapsular extension
(table 3). PSA values at the time of diagnosis tended to
be higher in men who carried one or more variant gen-
otypes. However, this effect was not statistically signif-
icant according to a Kruskal-Wallis x2 test, presumably
because of the relatively small sample size and the high
degree of variability in PSA. When divided at the sample
median PSA value, 16.8% of men with higher PSA values
carried the Leu217 or Thr541 genotype compared with
8.7% of men with lower PSA values (FET ).Pp 0.026
When broken into tertiles, 21.1% of CaP case subjects
with the highest tertile of PSA carried the Leu217 or
Thr541 genotype compared with 10.1% in the two low-
est tertiles (FET ). These analyses are highlyPp .014
preliminary, but suggest that additional studies of the
role of HPC2/ELAC2 genotype and disease severity
should be pursued.
In contrast to genes that confer relatively high disease
risk, we report odds ratio effects associated with HPC2/
ELAC2 that are relatively small. However, a relatively
large proportion of CaP may be explained by genotypes
at HPC2/ELAC2, because Leu217/Thr541 genotypes
are relatively common. If we assume a Leu217/Thr541
carrier frequency in the U.S. population to be ,pp .04
and the effect of this allele is OR p 2.4 (table 2), the
percent of CaP risk caused by this genotype can be es-
timated by use of the formula 100%# p(OR
(Lillienfeld and Lillienfeld 1980).1)/[p(OR 1) 1]
The proportion of CaP in the referent population that
would be explained by the common missense genotypes
is 5.3%. This proportion does not consider other vari-
ants (e.g., frameshift mutations) identified by Tavtigian
et al. (2000), but it does suggest that these common
missense changes may explain a relatively large propor-
tion of prostate cancer case subjects in the population.
We also considered a number of potential study lim-
itations. Our correction for race as a confounder in mul-
tiple logistic-regression models (table 2) and our subset
analysis among white subjects minimizes the potential
for population stratification as an explanation for the
present findings (Wacholder et al. 2000). It is unlikely
that genotyping errors could account for an elevated
proportion of HPC2/ELAC2 in control subjects relative
to case subjects, as most variant genotypes and some
nonvariant genotypes were confirmed by direct sequenc-
ing. Therefore, it is unlikely that genotyping errors in-
duced significant bias in our results. Misclassification of
case or control status could also have influenced the
inferences of this study. All case subjects were confirmed
by review of medical records, and the vast majority are
being followed actively for their disease by the clinicians
involved in this study. Thus, it is highly unlikely that
case subjects have been misclassified. No control subject
reported ever being told he had a diagnosis of CaP, and
no control subjects had elevated serum PSA or abnormal
DRE. Review of medical records confirmed that no con-
trol subject was diagnosed with CaP. However, control
subjects could have had clinically undetected disease,
and this misclassification might bias the reported OR.
If we assume that 10% of control subjects had a clini-
cally undetected disease, the unadjusted OR associated
with the Leu217/Thr541 variant would be 2.07 versus
2.11, when the actual observed data in table 2 are used.
Since the control-subject sample had a clinically normal
DRE and serum PSA, it is highly unlikely that as many
as 10% of control subjects were misclassified, and it is
unlikely that the OR estimates are substantially biased
because of control-subject misclassification.
Although the present results suggest that HPC2/
ELAC2 is associated with CaP risk, additional confirm-
atory epidemiological and basic science studies will be
required to better understand the association reported
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here. Nonetheless, this report suggests that HPC2/
ELAC2 is involved in the etiology of CaP in men as-
certained without respect to family history or other de-
terminants of CaP risk.
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